Financial Analysis: ChronoScale Corporation Common Stock (NASDAQ:CHRN) & CI&T (NYSE:CINT)

CI&T (NYSE:CINT) and ChronoScale Corporation Common Stock (NASDAQ:CHRN) are both small-cap technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings.

Analyst Recommendations

This is a breakdown of current ratings and price targets for CI&T and ChronoScale Corporation Common Stock, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CI&T	2	2	7	0	2.45
ChronoScale Corporation Common Stock	1	1	0	0	1.50

CI&T presently has a consensus target price of $6.41, suggesting a potential upside of 91.66%. ChronoScale Corporation Common Stock has a consensus target price of $6.00, suggesting a potential downside of 72.76%. Given CI&T’s stronger consensus rating and higher probable upside, equities analysts clearly believe CI&T is more favorable than ChronoScale Corporation Common Stock.

Risk & Volatility

CI&T has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, ChronoScale Corporation Common Stock has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.

Profitability

This table compares CI&T and ChronoScale Corporation Common Stock’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CI&T	7.90%	13.19%	7.32%
ChronoScale Corporation Common Stock	-135.66%	-197.81%	-74.17%

Earnings & Valuation

This table compares CI&T and ChronoScale Corporation Common Stock”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CI&T	$489.65 million	0.92	$40.62 million	$0.31	10.79
ChronoScale Corporation Common Stock	$12.80 million	6.13	-$11.69 million	($5.38)	-4.09

CI&T has higher revenue and earnings than ChronoScale Corporation Common Stock. ChronoScale Corporation Common Stock is trading at a lower price-to-earnings ratio than CI&T, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

92.4% of CI&T shares are owned by institutional investors. Comparatively, 6.4% of ChronoScale Corporation Common Stock shares are owned by institutional investors. 6.9% of ChronoScale Corporation Common Stock shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

CI&T beats ChronoScale Corporation Common Stock on 11 of the 14 factors compared between the two stocks.

About CI&T

CI&T, Inc. provides strategy, design and software engineering services to enable digital transformation. The firm’s solutions and services include Digital Strategy, Customer-Centric Design and Top-of-the-Line Software Engineering. The company was founded by Cesar Nivaldo Gon, Bruno Guiçardi Neto and Fernando Matt Borges Martins on June 7, 2021 and is headquartered in Sao Paulo, Brazil.

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.